Physicians' Academy for Cardiovascular Education

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - Imperial College London, UK

Video navigation menu

  • Available interventions that reduce CVD 0:47
  • The role of BET inhibition in the development of CVD 3:10
  • Observed reduction in CVD events with apabetalone 4:38
  • Aim and study design of BETonMACE 7:36

Educational information

This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.

Faculty

Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

View slides of prof. Ray

Share this page with your colleagues and friends: